A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02).
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 18342381.
- Also identified by DOI 10.1016/j.radonc.2008.02.006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
RTOG 95-02 assessed patient tolerance to hypoxic cell radiosensitizer, etanidazole (SR-2508), combined with radiosurgery. Patients had primary or metastatic brain tumors and previously localized or whole brain irradiation. The toxicity is reported in three groups of patients according to the tumor size. Etanidazole doses of 12g/m2 combined with radiosurgery were well tolerated.
Medical subject headings
- Brain Neoplasms
- Etanidazole
- Radiation-Sensitizing Agents
- Radiosurgery